Victoza, Novo Nordisks best selling type 2 diabetes drug is now commercially available in China. Victoza, (liraglutide injection), the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analog, was approved for type 2 diabetes by the Chinese State Food and Drug Administration in March 2011.Victoza is indicated in China as an add-on to metformin or sulphonylurea (SU) in people with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin or SU. Victoza has been proven to lower blood sugar levels, reduce body weight, lower systolic blood pressure, and shows improvements in measurements of beta cell function. In addition, Victoza has a low risk of hypoglycemia and a demonstrated safety profile.
Victoza has been commercially launched in more than 39 countries including the US, Japan, the Arabian Peninsula, and a number of countries in Europe, Asia and South America. Victoza was approved in June 2009 by the European Commission in all 27 European Union member states. In Europe Victoza is indicated for treatment of adults with type 2 diabetes mellitus to achieve glycemic control, in combination with or as an add-on to metformin, sulphonylurea and thiazolidinedione. In January 2010, Victoza was approved in the U.S. as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes.
